版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
AntibioticSeniorAcademicHalfDayMattRogers&JamesClaytonConsultantMicrobiologistsFebruary2011ObjectivesofthesessionBytheendofthesessionyouwillbeableto:DescribethefactorsthatneedtoconsideredwhenmakingthechoicetoprescribeanantibioticDevelopanunderstandingofkeypathogensandtheirsusceptibilitytoantibiotics.YouwillbeabletorelatethistotheantibioticpolicywithinyourTrustDefinewhatismeantbythetermAntibioticstewardshipBeawareofkeyDOHguidelines(Clostridiumdifficile)thatdirectthedevelopmentofantibioticpoliciesNametheantibioticsassociatedwithClostridiumdifficileStatetheminimumrequirementsofhowtoprescribeanantibioticNamethekeyissuesaroundrouteanddurationofantibioticsandhowthisaffectspatientsAntibioticstewardshipEnsurestheoptimisationofantibioticuseOnlyusewhennecessaryControlwhouseswhatControlrouteanddurationRespondtochangingneedsRespondtochangingEvidence/PoliciesRobustpolicing,reviewandstopstrategiesEprescribingAbitofbackground
ApottedhistoryofAntibioticsTheuseofantimicrobialsinthetreatmentofinfectionisoneofthetriumphsofmodernmedicine.
HistoryofAntibioticsBeforethediscoveryofthesulphurdrugsin1932,treatmentofinfectiousdiseasewaslimitedtomercury,arsenic,andquinine.Penicillinwasdiscoveredin1929.AlexanderFlemingHistoryofAntibioticsPenicillinwasnotmanufacturedonalargescalefornon-militaryuseuntil1949.
HistoryofAntibioticsDecadeAntibiotics1940s&1950sStreptomycinSyntheticpenicillinsCephalosporinsChloramphenicolTetracyclines.1960sQuinolones2000sOxazolidinone(Linezolid®)Glycylcycline(Tigecycline®)2010s??Longactingglycopeptides–phase3trialsResistancealwaysdevelopsExamplesStaphylococcusaureusPenicillinresistance1950/60sMRSA-Meticillinresistancesince1970sVRSA-Vancomycinresistancein2001EnterococciVRE:VancomycinResistantEnterococciColiformsQuinoloneresistanceESBLs:ExtendedSpectrumBeta-lactamasesMetalloBeta-lactamases
(NDM-1)AntimicrobialstewardshipAntimicrobialresistanceMultipleresistancegenesPlasmidsSpreadFactorsleadingtoresistance:InappropriateclinicaluseofABxPoorinfectioncontrolExcessiveABxuseinnonclinicalsettings:animalhusbandryshippingKeyantibioticchangesStopuseofcefuroximethroughouttheTrustUselowerriskaugmentin(butmonitorC.difficilerates)Reduceuseofciprofloxacin(considerpenicillinallergy)AntibioticpolicyavailableunderClinicalGuidelinesontheintranetAntibioticguidelinecreditcardsdistributedAntibioticstewardshipEnsurestheoptimisationofantibioticuseOnlyusewhennecessaryControlwhouseswhatControlrouteanddurationRespondtochangingneedsRespondtochangingEvidence/PoliciesRobustpolicing,reviewandstopstrategiesEprescribingAntibioticprescribing
What’simportant?WhenIsthereaninfection?HowTodiagnose.Whatspecimens?WhyWhatistheindication/Likelypathogens?WhatWhatantibiotic/route/durationWhen?DiagnosinginfectionisaCLINICALskillBasicsignsandsymptomsofinfectionPleaserememberapartfromsterilesites(urine/csf/bloodetc)mostareasyoucultureWILLgrowbacteriaWhennottoCSU-urinecloudy?ChestinfectionwithnoevidenceonCXRWoundwithserousexudateSloughyUlcersIsolatedspikesoftempTotreatahighWCCHow?HowtodiagnoseInfection???Whatspecimensdoyouneedtotake?Whatinvestigationsdoyouneedtoaskfor?Why?WhyarewegivingAntibioticsEmpirical/Prophylactic/TargetedKnowyourbasicMicrobiologyTheindication(UTI/LRTIetc)Thesetting(Pt+environment)HospitalvCommunity(feasibility)Thelikelypathogens(CRRS)ProphylaxisTherapygiventopreventaninfectionOftengivenaroundsurgeryGiventopatientspronetoparticularinfectionsContactsofNeisseriameningitidismeningitisGiventopatientswhoarespecificallyimmunocompromisedSplenectomyPCPprophylaxisinHIVSurgicalprophylaxisUsedtobegivenforseveraldaysEvidencenowsuggeststhatperi-operativeantibioticsadequateformost‘clean’operationsPrinciplesofantibioticprophylaxisTheuseofantibioticprophylaxisinvolvesadilemma;itishighlyeffectiveinpreventinginfection,butcanpromoteresistance.
Limittothoseindividualsinwhomtheriskofinfectionishigh.PrinciplesofantibioticprophylaxisWhichantibiotics?shouldbetargetedtothemostlikelypathogens.When?administrationasnearthetimeofincisionaspossible.Intravenousantibioticsshouldbegivenduringtheinductionofanaesthesiawithrepeatdosesforlongerprocedures.
Duration:keeptoaminimum(ofteneventoasingle-dose)toreducethechanceofresistancedeveloping.
Thebenefitsofpost-operativeprophylaxislastingmorethan12hhavenotbeenproven.IndicationsforantibioticprophylaxisContaminatedordirtyoperationspresenceofbowelcontents,pus,orinfectedforeignmaterialInsertionofgraftorprosthesiswheredevelopmentofinfectionwouldbeserious.ImmunocompromisedpatientsPatientswithcardiovascularabnormalities,mayrequirespecificantibioticprophylaxistoreducetheriskofendocarditis
(NICEguidelines,BSACguidelines)
RiskFactorsfor
SurgicalSiteInfectionPatient:ExtremesofagePoornutritionalstateObesityDiabetesmellitusSmokingCo-existinginfectionsatothersitesBacterialcolonisation(e.g.MRSA)ImmunosuppressionProlongedpostoperativestayOperationLengthofsurgicalscrubSkinantisepsisPreoperativeshavingPreoperativeskinprepLengthofoperationAntimicrobialprophylaxisOperatingtheatreventilationInadequateinstrumentsterilisationForeignmaterialinsurgicalsiteSurgicaldrainsSurgicaltechniqueincludinghaemostasis,poorclosure,tissuetraumaPostoperativehypothermiaSIGN:
ScottishIntercollegiateGuidelinesNetworkwww.sign.ac.uk
www.sign.ac.uk/guidelines/fulltext/104/index.html
SIGNqrg104.pdfEmpiricaltherapyTherapygivenwithoutknowingthecausativeorganismChoicebasedonpracticalexperienceandevidencebasedmedicine‘Bestguesstherapy’,unlikelytocoverallpossibilitiesTargetedtherapyTherapygivenwhentheinfectionandcausativeorganismisknownThisisthebestwayofeffectivetreatmentWeshouldknowtheactualsensitivityoftheoffendingpathogenWhat-ConsiderationsintherapyChoiceofagentincludes:RecentDOHguidance(Clostridiumdifficile)–HasalteredpoliciesRangeofpathogens(Why?)Infectionsite/drugpenetrationPatientfactors(allergy)TheaboveshouldbecoveredbyyourantibioticpolicyCombinationtherapy(synergy/antagonism)Dose/FrequencyRoute–IV/oralIV/oralswitchDuration(5-7daysformostinfection)PatientfactorsAllergyOthermedications(interactions)CantheytakePOToleranceComplianceInfectionsiteDrugpenetratione.g.Antibioticsaren’talwaystheanswerInfectionprostheses-SURGERYBone/SofttissueinfectionsSomedrugsliketheaminoglycosidesdonotpenetratewellMeningitisManydrugswillnotpenetrateCSFwellIVororalWhataretheconsiderationsDependsonsiteofinfectionOralbioavailabilityoftheantibioticClearaim/endpoint(treatment/suppression)LicencingMAUAudit
ZoeCampbellF2SHOOnlythosewithSeverepneumoniaaccordingtoCURBcriteriashouldreceiveIVantibiotics18outof25patientsreceivedIVantibiotics18patientswereclassifiedmild/mod(?Oralantibiotics)7patientswereclassifiedsevere(?IVantibiotics)I.V.Oral
Mild/ModerateSevereMAUAudit:IV/OralSwitchOnly2outof25(8%)patientshadanIVtooralswitch
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2019闽教版小学信息技术三年上册全集
- 2024年环己酮市场前景分析:环己酮亚太地区市场占比超过40%
- 2024最好的生日祝福语
- 2024-2025学年初中信息技术(信息科技)第五册电子工业社版(2022)教学设计合集
- 18岁成人礼家长对孩子的寄语范文三篇
- 高中化学必修2《乙醇》说课稿
- 2024学校反欺凌与暴力防治机制
- 产品设计与开发习题与答案(运营管理)
- 小学音乐名曲欣赏模拟试卷
- 艺术与科技的融合-数字化时代的创意设计思维
- 项目试运行方案(模板)
- 胸痛健康教育(课堂PPT)
- 工人生活区宿舍移交单
- 【图文】船舶靠离泊码头安全操作
- 医院消毒卫生标准GB-15982-2012.
- 专利审查协作中心笔试重点词汇(仅供参考)
- 《植物蛋白质组学》PPT课件.ppt
- 最新物业公司向地产公司要的前期开办费的解释资料
- Excel股票交易记录表
- 标识标牌施工组织设计(完整版)
- 安迪沃霍尔 波普ppt课件
评论
0/150
提交评论